Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology

2 Aug 2021

Abstract excerpt

OBJECTIVE: Tau hyperphosphorylation at threonine 217 (pT217) in cerebrospinal fluid (CSF) has recently been linked to early amyloidosis and could serve as a highly sensitive biomarker for Alzheimer's disease (AD). However, it remains unclear whether other tauopathies induce pT217 modifications. To determine if pT217 modification is specific to AD, CSF pT217 was measured in AD and other tauopathies. METHODS: Using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Amyloidosis: Diagnosis, Treatment, Outcomes
Share to Dementia and Cognitive Impairment Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34342183
DOI: 10.1002/acn3.51435

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathologyPMID 34342183Read ↗

CNS-selective plasma p-tau217 accurately captures Alzheimer’s disease pathology and progressionSemantic proximity Read ↗

Association of Plasma Phosphorylated Tau 217 With Clinical Deterioration Across Alzheimer Disease StagesSemantic proximity Read ↗

A Comprehensive Head-to-Head Comparison of Key Plasma Phosphorylated Tau 217 Biomarker TestsSemantic proximity Read ↗

Novel genetic variants in MAPT and alterations in tau phosphorylation in amyotrophic lateral sclerosis post‐mortem motor cortex and cerebrospinal fluidSemantic proximity Read ↗

Plasma p‐tau231 and p‐tau217 inform on tau tangles aggregation in cognitively impaired individualsSemantic proximity Read ↗

Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s diseaseSemantic proximity Read ↗

Cross-sectional study of plasma phosphorylated Tau 217 in persons without dementiaSemantic proximity Read ↗

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.Semantic proximity Read ↗

Plasma p-tau217, p-tau181, and Aβ42 Predicts Amyloid PET Positivity in Cognitively Unimpaired AdultsSemantic proximity Read ↗

An in-depth analysis of phosphorylated tau in amyotrophic lateral sclerosis post-mortem motor cortex and cerebrospinal fluidSemantic proximity Read ↗

Robustness of plasma p-Tau217 diagnostic thresholds for Alzheimer’s disease across various clinical populations and laboratory environmentsSemantic proximity Read ↗

Pittsburgh plasma p-tau217: classification accuracies for autosomal dominant and sporadic Alzheimer’s disease in the communitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.